How has been the historical performance of Fredun Pharma?

Answer:The historical performance of Fredun Pharma shows a steady growth in various financial metrics over the years, particularly highlighted in the fiscal year ending March 2025.

Breakdown:
In the fiscal year ending March 2025, Fredun Pharma reported net sales of 456.27 crore, with total operating income matching this figure as there was no other operating income. The total expenditure, excluding depreciation, was 401.36 crore, leading to an operating profit (PBDIT) of 54.91 crore, which reflects an operating profit margin of 12.16%. After accounting for interest expenses of 22.38 crore and depreciation of 5.04 crore, the profit before tax stood at 27.49 crore, resulting in a profit after tax of 19.74 crore, translating to a PAT margin of 4.37%. The company’s earnings per share (EPS) was reported at 41.82, with a diluted EPS of 44.83. On the balance sheet, total assets increased to 307.60 crore in March 2024, up from 257.28 crore in March 2023, while total liabilities also rose to 307.60 crore, indicating a balanced growth in assets and liabilities. The book value per share adjusted was 255.15 in March 2024, reflecting a significant increase from previous years. Cash flow analysis reveals a net cash outflow of 2.00 crore in March 2024, with cash flow from operating activities remaining at zero, indicating challenges in cash generation despite the growth in sales and profits.